Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an international surveillance programme

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 18, Issue 6, 1999, Pages 403-408

  Jones, M E ^a   Schmitz, F J ^a   Fluit, A C ^a   Verhoef, J ^a   Acar, J ^b   Gupta, R ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SAINT JOSEPH HOSPITAL   (France)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEFACLOR; CEFAZOLIN; CEFEPIME; CEFIXIME; CEFOTAXIME; CEFOXITIN; CEFPODOXIME; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; SPARFLOXACIN; STREPTOMYCIN; TROVAFLOXACIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; EUROPE; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS;

EID: 0032750429     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050308     Document Type: Article

References (19)

1. 1. Cohen ML: Epidemiology of drug resistance; implications for a post antimicrobial era. Science (1992) 257:1050-1055
2. 2. Gold SG, Moellering RC: Antimicrobial drug resistance. New England Journal of Medicine (1996) 335:1445-1453
3. 3. Livermore DM, Yuan M: Antimicrobial agent resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. Journal of Antimicrobial Chemotherapy (1996) 38:409-424
4. 4. Burwen DR, Banjeree SN, Gaynes RP, and the National Nosocomial Infections Surveillance System: Ceftazidime resistance among selected gram-negative bacilli in the United States. Journal of Infectious Diseases (1994) 170:1622-1625
5. 5. Jarlier V, Fosse T, Phillippon A, and the ICU Study Group: Antibiotic susceptibility in aerobic gram-negative bacilli isolated in intensive care units in French teaching hospitals (ICU Study). Intensive Care Medicine (1996) 22:1057-1065
6. 6. Spencer RC, Bauernfeind A, Garcia-Rodriguez J, Jarlier V, Pfaller M, Turnidge J, Voss A: Surveillance of the current resistance of nosocomial pathogens to antibacterials. Clinical Microbiology and Infection (1997) 3, Supplement 1:21-35
7. 7. Spencer RC: An 8 year microbe base survey of the epidemiology, frequency and antimicrobial agent susceptibility of Pseudomonas aeruginosa hospital isolates in the United Kingdom. Journal of Antimicrobial Chemotherapy (1996) 37:295-301
8. 8. Bergogne-Berezin E, Towner KJ: Acinetobacter spp. as nosocomial pathogens: microbiological, clinical and epidemiological features. Clinical Microbiology Reviews (1996) 9:148-165
9. 9. Spencer RC: The emergence of epidemic, multiple-antibiotic resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacea. Journal of Hospital Infection (1995) 30, Supplement 1:453-464
10. 10. Howe RA, Brown NM, Spencer RC: The new threats of gram-positive pathogens: re-emergence of things of the past. Journal of Clinical Pathology (1996) 49:444-449
11. 11. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I: Methicillin resistance in Europe. European Journal of Clinical Microbiology & Infectious Diseases (1994) 13:50-55
12. 12. Woodford N, Johnson AP, Morrison D, Speller DCE: Current pespectives in glycopeptide resistance. Clinical Microbiology Reviews (1995) 8:585-615
13. 13. American Society for Microbiology: Report of the ASM Task Force on Antibiotic Resistance. Antimicrobial Agents and Chemotherapy (1995) 39:Supplement 6:1-23
14. 14. Lorian V: The need for surveillance for antimicrobial resistance. Infection Control and Hospital Epidemiology (1995) 16:638-641
15. 15. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing. Supplement tables M100-S8. NCCLS, Wayne, PA (1998)
16. 16. Hiramatsu K, Hanaki H, Yabuta K, Oguri T, Tenover FC: Staphylococcus aureus with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy (1997) 40:135-136
17. 17. Schmitz F-J, Jones ME: Antibiotics in the treatment of infections caused by MRSA. What are the choices? International Journal of Antimicrobial Agents (1997) 9:1-19
18. 18. Jones ME, Sader H, Verhoef J, Acar J, Jones RN: The current state of susceptibility to glycopeptides in Staphylococcus aureus from an international surveillance program. Journal of Antimicrobial Chemotherapy (1998) 42:119-121
19. 19. Stanford DG, Georgouras KE, Konya J, Pang B: Toxic streptococcal syndrome. Australasian Journal of Dermatology (1997) 38:158-160